Summary

The 7 major mitochondrial myopathies markets reached a value of US$ 22.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 34.8 Million by 2034, exhibiting a growth rate (CAGR) of 4.07% during 2024-2034.

The mitochondrial myopathies market has been comprehensively analyzed in IMARC's new report titled "Mitochondrial Myopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mitochondrial myopathies are a group of rare genetic disorders that affect the function of mitochondria, the energy-producing organelles within cells. The symptoms of mitochondrial myopathies can vary widely, depending on the specific type of ailment and the severity of the condition. However, some of the common symptoms are muscle weakness and wasting, exercise intolerance, fatigue, difficulty in breathing, etc. Various other possible indications include vision and hearing problems, seizures, movement disorders, developmental delays in children, etc. The diagnosis of mitochondrial myopathies involves a combination of clinical evaluations, such as muscle biopsy, electromyography, blood tests, etc., along with genetic testing to identify specific mutations. Several imaging studies, such as MRIs and CT scans, are used to evaluate muscle and organ function. Additionally, a muscle biopsy may be performed to assess the structure and function of the muscle tissue, which can be particularly helpful in diagnosing certain types of mitochondrial myopathies.

The increasing prevalence of inherited mitochondrial DNA mutations is primarily driving the mitochondrial myopathies market. In addition to this, the escalating utilization of several medications, such as idebenone, dichloroacetate, L-carnitine, etc., to improve mitochondrial function and reduce symptoms related to the condition is further creating a positive outlook for the market. Moreover, the rising usage of biochemical testing, including enzyme assays, respiratory chain analysis, mitochondrial DNA analysis, etc., to help assess the function of the mitochondria and detect abnormalities that are characteristic of mitochondrial myopathies is also bolstering the market growth. Apart from this, several key players are making extensive investments in identifying biomarkers, such as creatine kinase, serum FGF-21 levels, coenzyme Q10, etc., which can aid in diagnosing and monitoring the disorder. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of mitochondrial replacement therapy, which involves replacing a patient's dysfunctional mitochondria with healthy ones from a donor, as a potential treatment option is further propelling the market growth. Besides this, the ongoing advancements in the field of genetic testing, such as the development of high-throughput genetic sequencing technologies to identify genetic mutations that cause the ailment, are expected to drive the mitochondrial myopathies market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the mitochondrial myopathies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mitochondrial myopathies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mitochondrial myopathies market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mitochondrial myopathies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mitochondrial myopathies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mitochondrial myopathies marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the mitochondrial myopathies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mitochondrial myopathies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mitochondrial myopathies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of mitochondrial myopathies across the seven major markets?
What is the number of prevalent cases (2018-2034) of mitochondrial myopathies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mitochondrial myopathies by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of mitochondrial myopathies by type across the seven major markets?
How many patients are diagnosed (2018-2034) with mitochondrial myopathies across the seven major markets?
What is the size of the mitochondrial myopathies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mitochondrial myopathies?
What will be the growth rate of patients across the seven major markets?

Mitochondrial Myopathies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mitochondrial myopathies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mitochondrial myopathies market?
What are the key regulatory events related to the mitochondrial myopathies market?
What is the structure of clinical trial landscape by status related to the mitochondrial myopathies market?
What is the structure of clinical trial landscape by phase related to the mitochondrial myopathies market?
What is the structure of clinical trial landscape by route of administration related to the mitochondrial myopathies market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Mitochondrial Myopathies - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Mitochondrial Myopathies - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Mitochondrial Myopathies - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)

8 Mitochondrial Myopathies - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Mitochondrial Myopathies - Unmet Needs

10 Mitochondrial Myopathies - Key Endpoints of Treatment

11 Mitochondrial Myopathies - Marketed Products
11.1 List of Mitochondrial Myopathies Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Mitochondrial Myopathies - Pipeline Drugs
12.1 List of Mitochondrial Myopathies Pipeline Drugs Across the Top 7 Markets
12.1.1 Bocidelpar - Mitobridge
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Mavodelpar - Reneo Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Elamipretide - Stealth BioTherapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 KH176 - Khondrion
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Mitochondrial Myopathies - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Mitochondrial Myopathies – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Mitochondrial Myopathies - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mitochondrial Myopathies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mitochondrial Myopathies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mitochondrial Myopathies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mitochondrial Myopathies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mitochondrial Myopathies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mitochondrial Myopathies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mitochondrial Myopathies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mitochondrial Myopathies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mitochondrial Myopathies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mitochondrial Myopathies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mitochondrial Myopathies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mitochondrial Myopathies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mitochondrial Myopathies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mitochondrial Myopathies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mitochondrial Myopathies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mitochondrial Myopathies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mitochondrial Myopathies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mitochondrial Myopathies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mitochondrial Myopathies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mitochondrial Myopathies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mitochondrial Myopathies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mitochondrial Myopathies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mitochondrial Myopathies - Access and Reimbursement Overview

16 Mitochondrial Myopathies - Recent Events and Inputs From Key Opinion Leaders

17 Mitochondrial Myopathies Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Mitochondrial Myopathies Market – Strategic Recommendations

19 Appendix